Dashboard
Manage Tickers

PFEPFIZER INC

NYSE pfizer.com


$ 29.00 $ 0.34 (1.19 %)    

Friday, 12-Jul-2024 12:44:21 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 496.26 $ 4.47 (0.91 %)
DIA $ 400.57 $ 1.74 (0.44 %)
SPY $ 560.92 $ 3.42 (0.61 %)
TLT $ 93.61 $ 0.10 (0.11 %)
GLD $ 223.39 $ 1.36 (0.61 %)
$ 28.66
$ 28.90
$ 28.99 x 100
$ 29.00 x 614
$ 28.79 - $ 29.14
$ 24.83 - $ 35.80
47,322,551
na
163.28B
$ 0.57
nm
TBD
na
na ($ 0.06)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 11-08-2023 10-01-2023 10-Q
4 08-09-2023 07-02-2023 10-Q
5 05-10-2023 04-02-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 11-09-2022 10-02-2022 10-Q
8 08-10-2022 07-03-2022 10-Q
9 05-11-2022 04-03-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-12-2021 10-03-2021 10-Q
12 08-12-2021 07-04-2021 10-Q
13 05-13-2021 04-04-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-27-2020 10-Q
16 08-06-2020 06-28-2020 10-Q
17 05-07-2020 03-29-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-07-2019 09-29-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 07-01-2018 10-Q
25 05-10-2018 04-01-2018 10-Q
26 02-22-2018 12-31-2017 10-K
27 11-09-2017 10-01-2017 10-Q
28 08-10-2017 07-02-2017 10-Q
29 05-11-2017 04-02-2017 10-Q
30 02-23-2017 12-31-2016 10-K
31 11-10-2016 10-02-2016 10-Q
32 08-11-2016 07-03-2016 10-Q
33 05-12-2016 04-03-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-05-2015 09-27-2015 10-Q
36 08-06-2015 06-28-2015 10-Q
37 05-07-2015 03-29-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-06-2014 09-28-2014 10-Q
40 08-07-2014 06-29-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-presence---goldman-sachs
With Oral Anti-Obesity Candidate Developme...
07/12/2024 16:26:42

Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with...

pfizer-l3harris-technologies-and-more-cnbcs-final-trades
Pfizer, L3Harris Technologies And More: CN...
07/12/2024 13:14:57

Pfizer selected Danuglipron, its once-daily weight loss drug, for continued advancement based on an ongoing pharmacokinetic study.

why-pfizer-stock-is-moving-higher-on-thursday
Why Pfizer Stock Is Moving Higher on Thursday
07/11/2024 17:34:58

Pfizer announced it will advance development of its once-daily Danuglipron.

Core News & Articles
CNBC Halftime Report Final Trades: Pfizer,...
07/11/2024 17:02:07

pfizer-advances-once-daily-weight-loss-pill-as-it-catches-up-to-tap-the-lucrative-market
Pfizer Advances Once-Daily Weight-Loss Pil...
07/11/2024 13:45:33

Pfizer advances its once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, after positive Pha...

Core News & Articles
CureVac Announced The Latest Trial Dates F...
07/11/2024 11:20:10

New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First...

pfizer-announced-that-based-on-results-from-the-ongoing-pharmacokinetic-study-the-company-has-selected-its-preferred-once-daily-modified-release-formulation-for-danuglipron-pfizer-plans-to-conduct-dose-optimization-studies-in-the-second-half-of-2024
Pfizer Announced That Based On Results Fro...
07/11/2024 10:50:31

barclays-maintains-equal-weight-on-pfizer-raises-price-target-to-30
Barclays Maintains Equal-Weight on Pfizer,...
07/10/2024 23:23:43

Barclays analyst Carter Gould maintains Pfizer (NYSE:PFE) with a Equal-Weight and raises the price target from $28 to $30.

pfizer-and-mainz-provide-examples-of-using-emerging-technology-for-good
Pfizer And Mainz Provide Examples Of Using...
07/10/2024 17:04:40

This week, Pfizer Inc (NYSE: PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European indus...

cantor-fitzgerald-reiterates-overweight-on-pfizer-maintains-45-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/10/2024 14:08:31

Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.

Core News & Articles
Evotec And Pfizer Announce Multi-Year Coll...
07/10/2024 06:23:38

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases The re...

pfizer-launches-process-to-identify-chief-scientific-officer-successor
Pfizer Launches Process To Identify Chief ...
07/09/2024 17:11:27

Pfizer announced its starting the process to find a new chief scientific officer and president of Pfizer Research and Development.

pfizer-options-trading-a-deep-dive-into-market-sentiment
Pfizer Options Trading: A Deep Dive into M...
07/09/2024 15:31:21

pfizer-is-looking-for-a-successor-for-dr-mikael-dolsten-pfizers-chief-scientific-officer-and-president-of-pfizer-research--development-who-will-depart-the-company-after-more-than-15-years
Pfizer Is Looking For A Successor For Dr. ...
07/09/2024 10:47:16

pfizers-rsv-vaccine-abrysvo-clears-concerns-over-preterm-birth-risk-safety-for-pregnant-women-new-study-shows
Pfizer's RSV Vaccine Abrysvo Clears Concer...
07/08/2024 17:30:51

Pfizer's RSV vaccine, Abrysvo, for pregnant women shows no increased risk of pre-term births, according to a study. Researc...

ozempic-maker-novo-nordisk-reprimanded-by-uk-regulators-for-payment-disclosure-failures
Ozempic Maker Novo Nordisk Reprimanded by ...
07/05/2024 16:28:59

UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches ...

Core News & Articles
UPDATE: Circulations Of Report Titled 'FDA...
07/05/2024 15:09:31

https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-evaluate-potential-risk-neural-tube-bi...

Core News & Articles
Reported September 6, 2018, 'FDA to evalua...
07/05/2024 14:54:33

what-the-options-market-tells-us-about-pfizer
What the Options Market Tells Us About Pfizer
07/03/2024 18:01:27

gsk-buys-full-rights-to-investigational-covid-19-and-influenza-vaccines-from-curevac-for-around-15b
GSK Buys Full Rights To Investigational Co...
07/03/2024 12:01:25

GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gai...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)
07/30/2024 Rivian Automotive, Inc. (RIVN)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)